#United States #Securities Fraud #Bensalem #Howard G. Smith #ImmunityBio

Class Action Lawsuit Opportunity for ImmunityBio Investors

Investors who have faced significant losses in ImmunityBio, Inc. (NASDAQ: IBRX) are encouraged to consider leading a class action lawsuit against the company. The Law Offices of Howard G. Smith have recently made this announcement, revealing a timely opportunity for those affected to assert their rights and seek justice.

Overview of the Situation

Between January 19, 2026, and March 24, 2026, shareholders allege that the company, led by Defendant Soon-Shiong, misrepresented the potential of its drug Anktiva. These claims suggest that the positive assertions made regarding the company’s business, operations, and future prospects were misleading or lacked a reasonable basis. As a result, investors experienced substantial financial setbacks.

Key Details of the Lawsuit

The lawsuit revolves around the failure to disclose pertinent information that inflated the perceived capabilities of Anktiva, thus misguiding investors. It’s crucial that affected shareholders act swiftly—interested parties should connect with the Law Offices of Howard G. Smith before the deadline of May 26, 2026, to join the class action.

How to Get Involved

The Law Offices of Howard G. Smith are actively seeking investors to lead this lawsuit. If you are among those who experienced financial losses due to alleged misinformation from ImmunityBio, you can contact the firm to discuss your legal options. You can reach out via email at email protected or by phone at (215) 638-4847. Additional information can also be found on their website: www.howardsmithlaw.com.

Your Rights as an Investor

Participation in this lawsuit may allow you to reclaim losses associated with your investment in ImmunityBio. Even if you are unsure about taking legal action, it’s advisable to stay informed. You may choose to retain legal counsel of your choice or remain a passive member of the class action.

Understanding what constitutes securities fraud is vital for every investor. Not only does it shine a light on the responsibilities companies hold towards their shareholders, but it also emphasizes the rights of investors to seek remedies for damages caused by negligent or misleading behavior.

Conclusion

The ongoing developments in this case highlight the importance of transparency in corporate communications and the potential consequences when companies fall short of this obligation. Investors affected by the alleged fraudulent activities of ImmunityBio have a significant opportunity to take action. By joining this class action lawsuit, shareholders can potentially mitigate their losses and hold those responsible accountable. For further details about the lawsuit, please contact the Law Offices of Howard G. Smith.

Stay tuned for more updates on this unfolding situation, and remember that it’s essential to stay proactive in understanding your rights as an investor.